Nivolumab combined with radical chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): An investigator-initiated, open-label, multicenter, single-arm, phase II clinical trial.Cheng Xu, Jun Ma, Xiaozhong Chen et al.|Journal of Clinical Oncology|2024Cited by 3
Nivolumab combined with chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): A multicenter, single-arm, phase II clinical trial.Cheng Xu, Jun Ma, Liangfang Shen et al.|Journal of Clinical Oncology|2024Cited by 0